Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells
- PMID: 23128397
- DOI: 10.1038/onc.2012.477
Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells
Abstract
In embryonic stem (ES) cells, bivalent chromatin domains containing H3K4me3 and H3K27me3 marks silence developmental genes, while keeping them poised for activation following differentiation. We have identified gene sets associated with H3K27me3 and H3K4me3 marks at transcription start sites in a high-grade ovarian serous tumour and examined their association with epigenetic silencing and malignant progression. This revealed novel silenced bivalent marked genes, not described previously for ES cells, which are significantly enriched for the PI3K (P<10(-7)) and TGF-β signalling pathways (P<10(-5)). We matched histone marked gene sets to gene expression sets of eight normal fallopian tubes and 499 high-grade serous malignant ovarian samples. This revealed a significant decrease in gene expression for the H3K27me3 and bivalent gene sets in malignant tissue. We then correlated H3K27me3 and bivalent gene sets to gene expression data of ovarian tumour 'stem cell-like' sustaining cells versus non-sustaining cells. This showed a significantly lower expression for the H3K27me3 and bivalent gene sets in the tumour-sustaining cells. Similarly, comparison of matched chemo-sensitive and chemo-resistant ovarian cell lines showed a significantly lower expression of H3K27me3/bivalent marked genes in the chemo-resistant compared with the chemo-sensitive cell line. Our analysis supports the hypothesis that bivalent marks are associated with epigenetic silencing in ovarian cancer. However it also suggests that additional tumour specific bivalent marks, to those known in ES cells, are present in tumours and may potentially influence the subsequent development of drug resistance and tumour progression.
Similar articles
-
Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis.Cancer Res. 2018 Mar 15;78(6):1383-1391. doi: 10.1158/0008-5472.CAN-17-1650. Epub 2018 Jan 16. Cancer Res. 2018. PMID: 29339543
-
Hypoxia increases genome-wide bivalent epigenetic marking by specific gain of H3K27me3.Epigenetics Chromatin. 2016 Oct 26;9:46. doi: 10.1186/s13072-016-0086-0. eCollection 2016. Epigenetics Chromatin. 2016. PMID: 27800026 Free PMC article.
-
Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells.Epigenetics. 2010 Nov-Dec;5(8):716-29. doi: 10.4161/epi.5.8.13014. Epub 2010 Nov 1. Epigenetics. 2010. PMID: 20676026 Free PMC article.
-
Bivalent Histone Modifications and Development.Curr Stem Cell Res Ther. 2018;13(2):83-90. doi: 10.2174/1574888X12666170123144743. Curr Stem Cell Res Ther. 2018. PMID: 28117006 Review.
-
Bivalent histone modifications in early embryogenesis.Curr Opin Cell Biol. 2012 Jun;24(3):374-86. doi: 10.1016/j.ceb.2012.03.009. Epub 2012 Apr 17. Curr Opin Cell Biol. 2012. PMID: 22513113 Free PMC article. Review.
Cited by
-
Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer.Curr Oncol. 2023 Dec 29;31(1):229-249. doi: 10.3390/curroncol31010015. Curr Oncol. 2023. PMID: 38248100 Free PMC article. Review.
-
Detection of metabolic adaptation in a triple-negative breast cancer animal model with [18F]choline-PET imaging as a surrogate for drug resistance.Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1261-1267. doi: 10.1007/s00259-023-06546-0. Epub 2023 Dec 14. Eur J Nucl Med Mol Imaging. 2024. PMID: 38095672
-
WDR82-Mediated H3K4me3 Is Associated with Tumor Proliferation and Therapeutic Efficacy in Pediatric High-Grade Gliomas.Cancers (Basel). 2023 Jun 30;15(13):3429. doi: 10.3390/cancers15133429. Cancers (Basel). 2023. PMID: 37444539 Free PMC article.
-
EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.Mol Cancer. 2023 May 20;22(1):85. doi: 10.1186/s12943-023-01786-y. Mol Cancer. 2023. PMID: 37210576 Free PMC article.
-
3D Tumor Models in Urology.Int J Mol Sci. 2023 Mar 25;24(7):6232. doi: 10.3390/ijms24076232. Int J Mol Sci. 2023. PMID: 37047203 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical